KDR and neoplasm: Most anti-angiogenic approaches focus on inhibiting the signaling pathway of pro-angiogenic factors, either by interacting with the factor itself (e.g., BVZ, the anti-VEGFA) or by blocking its receptor on the tumor cell surface (e.g., sunitinib, the anti-VEGFR).